<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE>Drug Interaction Knowledge Base 1.2</TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<H3>Drug Interaction Knowledge Base 1.2</H3>
<H2>ziprasidone_maximum_concentration_continuous_value</H2>
<HR>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE></TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<a name="
ziprasidone_maximum_concentration_continuous_value
"></a>
<b>Assertion:
ziprasidone maximum_concentration continuous_value
</b>
<BR>
<A NAME="Evidence"></A>
<P><TABLE border=2 cellpadding=4 cellspacing=1 width="100%">
<CAPTION align=top><STRONG>Evidence</STRONG></CAPTION>
<TR><TD Align=left ><STRONG>Evidence For (item 0)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771448</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br>route of administration: oral<br><br>study duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.<br><br>population: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;<br><br>ages: 18 - 49<br><br>C_max @ 10mg/day: 14.8ng/mL<br><br>14.8ng/mL x 1g/10^9ng x 1000mL/1L = 0.0000148g/L <br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>1.48e-05</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.01</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 1)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771448</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br><br>route of administration: oral<br><br>study duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.<br><br>population: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;<br><br>ages: 18 - 49<br><br>C_max @ 40mg/day: 44.6ng/mL<br><br>44.6ng/mL x 1g/10^9ng x 1000mL/1L = 0.0000446g/L <br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>4.46e-05</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.04</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 2)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771448</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br>route of administration: oral<br><br>study duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.<br><br>population: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;<br><br>ages: 18 - 49<br><br>C_max @ 80mg/day: 118.6ng/mL<br><br>118.6ng/mL x 1g/10^9ng x 1000mL/1L = 0.0001186g/L <br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>0.0001186</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.08</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 3)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771448</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br>route of administration: oral<br><br>study duration: &quot;Methods Single and multiple doses of ziprasidone were given orally (as two divided daily doses), at fixed dosages of 10 and 40 mg/day, and using titrated regimens of 40 +/- 80 and 40 +/-120 mg/day, for 14 days. All dosages were taken immediately after food.<br><br>population: 39 healthy, non-smoking, males. None were tested for known CYP450 phenotypes. &quot;In this double-blind, parallel-group study, subjects were randomised to receive placebo or one of four doses of ziprasidone&quot;<br><br>ages: 18 - 49<br><br>C_max @ 120mg/day: 139.4ng/mL<br><br>139.4ng/mL x 1g/10^9ng x 1000mL/1L = 0.0001394g/L <br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>0.0001394</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.12</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 4)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771449</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br><br>route of administration: oral<br><br>study duration: &quot;oral ziprasidone 40 mg/day, in two evenly divided daily doses, for 7 days, followed by a single 20 mg dose on day 8.&quot; <br><br>population: 35 participants including Eight young men, 11 young women (NOTE: three withdrew early on in the study), 8 elderly men and 8 elderly women where young is defined as 18-45 years of age and elderly is defined as (&gt; or = 65 years). All participants were considered healthy and the majority were white.<br><br>tested for known CYP450 polymorphisms? NO<br><br>ages: see above<br><br>C_max @ 40mg/day ziprasidone for 7 days (average of combined young and old C_max from Table 3): (69 + 85) / 2 = 77ng/mL<br><br>77ng/mL X 1g/10^9ng X 1000mL/1L = 0.000077g/L<br> <br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>7.7e-05</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.04</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence For (item 5)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_CT_Pharmacokinetic</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/10771449</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br>route of administration: oral<br><br>study duration: &quot;oral ziprasidone 40 mg/day, in two evenly divided daily doses, for 7 days, followed by a single 20 mg dose on day 8.&quot;<br><br>population: 35 participants including Eight young men, 11 young women (NOTE: three withdrew early on in the study), 8 elderly men and 8 elderly women where young is defined as 18-45 years of age and elderly is defined as (&gt; or = 65 years). All participants were considered healthy and the majority were white.<br><br>tested for known CYP450 polymorphisms? NO<br><br>ages: see above<br><br>C_max @ 20mg single dose ziprasidone (average of combined young and old C_max from Table 2): (56 + 60) / 2 = 58ng/mL <br><br>58ng/mL X 1g/10^9ng X 1000mL/1L = 0.000058g/L</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>maximum_concentration: </STRONG>5.8e-05</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>dose: </STRONG>0.02</TD>
<TD Align=left ><STRONG>numb_subjects: </STRONG>None</TD>
</TR>
</TABLE><P>

<BR>

</BODY> </HTML>

<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<BR><BR><a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-sa/3.0/88x31.png" /></a><br /><span xmlns:dct="http://purl.org/dc/terms/" href="http://purl.org/dc/dcmitype/Dataset" property="dct:title" rel="dct:type">Drug Interaction Knowledge Base (DIKB)</span> by <a xmlns:cc="http://creativecommons.org/ns#" href="http://www.dbmi.pitt.edu/person/richard-boyce-phd" property="cc:attributionName" rel="cc:attributionURL">Richard D. Boyce</a> is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/">Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License</a>.

<P><HR>
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<BR><IMG src="./images/logo.jpg" alt="logo.jpg" align="bottom">
<FONT SIZE="-1"><P>Copyright &#169 (c) 2005-2012 Richard David Boyce<BR>All Rights Reserved<BR>

Comments to author: <A HREF="mailto:&#114;db&#50;0 &#97;t &#112;it&#116; <&#100;ot&#62; e&#100;u">rdb20 at pitt <dot> edu</A><br>
Generated: Wed Jul 29, 2015 <BR><hr>
</FONT>
</BODY> </HTML>
